Three studies show the potential of an artificial pancreas & a less invasive glucose testing device and a 2-drug combo to improve glycemic measures.
A hybrid closed-loop insulin delivery system, or so-called “artificial pancreas,” appears to be safe and effective in patients with T1DM. A novel flash glucose testing device can reduce the time adults with well-controlled T1DM spend in hypoglycemia. A combination of exenatide and dapagliflozin can improve glycemic measures and cardiovascular risk factors better than either drug alone in patients with T2DM inadequately controlled on metformin monotherapy.
Artificial Pancreas Appears Safe and Effective. Abstract link.
A hybrid closed-loop insulin-delivery system results in reductions in both hypoglycemia and hyperglycemia with less glycemic variability compared with baseline data in patients with T1DM.
The hybrid closed-loop system can safely and effectively help manage T1DM in adolescents and adults at home.
Flash Glucose Monitor Reduces Time in Hypoglycemia. Abstract link.
A novel glucose monitoring technology may replace self-monitoring of blood glucose using finger sticks.
Patients who use the device can increase their self-monitoring, reduce time spent in hypoglycemia, and potentially increase time in optimum glucose range with less glucose variability and improvements in quality of life.
Two-Drug Combination Improves Glycemic Levels in T2DM. Abstract link.
For the first time, a study shows the effectiveness of a combination of a GLP-1 receptor agonist, exenatide, and a SGLT2 inhibitor, dapagliflozin, in T2DM patients uncontrolled on metformin monotherapy.
A combination of exenatide and dapagliflozin can lead to significantly greater reductions in terms of glycemic parameters, weight, and systolic blood pressure than either agent alone in T2DM patients inadequately controlled on metformin monotherapy.